ストックスクリーナーアプリを入手
14.01
4.79%
0.64
アフターアワーズ：
13.80
-0.21
-1.50%
Erasca Inc (ERAS) 最新ニュース
FinancialContentSecurities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - FinancialContent
ERAS INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials - Insider Monkey
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit - Caledonian Record
ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses - GlobeNewswire Inc.
Erasca sued for securities fraud over misleading drug claims, stock drops 45%. - Pluang
SHAREHOLDER ALERT: Erasca, Inc. Sued For Securities Fraud by Block & Leviton LLP; August 10 ... - Caledonian Record
SHAREHOLDER ALERT: Erasca, Inc. Sued For Securities Fraud - GlobeNewswire
Erasca Inc. (ERAS) Faces Selling Pressure as Shares Decline 3%KAMA Signal - newsline.com
BofA Securities Maintains Erasca(ERAS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents - Yahoo Finance
ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits
Venrock Adviser, LLC's Erasca Inc(ERAS) Holding History - GuruFocus
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations - Insider Monkey
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds - Insider Monkey
Erasca earnings on deck after ERAS-0015 data sparks debate - Investing.com
Erasca earnings on deck after ERAS-0015 data sparks debate By Investing.com - Investing.com Nigeria
Erasca Shares Rise After BofA Upgrade - Moomoo
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset - Barchart.com
Erasca, Inc. Stock 12‑Month Price Target Raised to $20.91, Implies 59% Upside - TradingView
BofA Securities Upgrades Erasca(ERAS.US) to Hold Rating, Raises Target Price to $16 - Moomoo
BofA Securities Upgrades Erasca to Neutral From Underperform, Adjusts Price Target to $16 From $9 - marketscreener.com
This KeyBanc Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday - Benzinga
BofA upgrades Erasca stock rating on pan-RAS drug activity By Investing.com - Investing.com South Africa
BofA upgrades Erasca stock rating on pan-RAS drug activity - Investing.com
ERAS: Phase I RAS-targeting agents show high NSCLC efficacy and strong safety, with key updates ahead - TradingView
Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20 - Insider Monkey
5 Best Growth Stocks Under $20 to Buy - Insider Monkey
Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Crescent Biopharma (CBIO) and Erasca (ERAS) - The Globe and Mail
Erasca Inc stock (US29479V1044): Q1 2026 loss and Nasdaq price move in focus - AD HOC NEWS
Erasca touts 'eye-popping' ERAS-0015 lung cancer data, FDA path at BofA conference - MSN
Erasca's RAS Pipeline Momentum Sparks Buy Debate as Biotech Stock Trades Near $13 in 2026 - International Business Times Australia
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% - The Globe and Mail
RTW INVESTMENTS, LP's Erasca Inc(ERAS) Holding History - GuruFocus
BofA Securities Maintains Erasca(ERAS.US) With Sell Rating, Maintains Target Price $9 - Moomoo
Erasca shares plunge 48% after legal challenge over key drug's intellectual property. - Pluang
Erasca to Present at the Jefferies Global Healthcare Conference - The Manila Times
Cancer drug developer Erasca to meet investors at Jefferies event - Stock Titan
Erasca Patent Dispute Puts ERAS-0015 And Investment Case Under Scrutiny - Yahoo Finance
Erasca Inc. (ERAS) Declines 3.15% as Stock Approaches Key Support AreaAlgorithmic Stock Picks - thelegaladvocate.com
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More - AOL.com
Erasca (ERAS) Is Up 9.9% After Merck Tie-Up And IP Challenge To ERAS-0015Has The Bull Case Changed? - simplywall.st
Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus - Sahm
ERAS Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerEarnings Quality Analysis - newsline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc.ERAS - PR Newswire
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion o - GuruFocus
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset - PR Newswire
Number of shareholders of Erasca, Inc. – NASDAQ:ERAS - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Erasca, Inc. (ERAS) And Encourages Shareholders to Reach Out - ACCESS Newswire
ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc. - Business Wire
4.65%
1.27%
大文字化:
|
ボリューム (24 時間):